Please Wait...

PINP // Procollagen Type I N-Propeptide

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

In bone, type I collagen constitute 90% of the organic matrix. Type I collagen is first synthetized as a type I procollagen and then cleaved at its two extremities. The two cleavage fragments, named N-terminal propeptide of type I collagen (PINP) and carboxy-terminal pro-peptide (PICP) are released and are measurable in blood. Their presence in the peripheral circulation is indicative of bone formation (but not specific)(Garnero et al., 2008; Naylor and Eastell, 2012). PINP is the biomarker of reference for bone formation chosen by The International Osteoporosis Foundation due to its robust nature and dynamic response to treatment (Vasikaran et al., 2011).

Bioclinica Lab employs an automated electro-chemiluminescence immunoassay for the measurement of PINP in serum.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

With many clinical trials slowed or terminated, investments in new technologies are difficult. Yet, a #CTMS with a… https://t.co/VRIhWWf4tE
Bioclinica (5 days ago)
With Bioclinica #CTMS, sponsors & CROs have access to a full-featured, scalable system - a single, centralized sour… https://t.co/7ACrv8cvuF
Bioclinica (1 week ago)
Now available: a DIY #EDC solution. From study start-up to close-out, Bioclinica EDC Solo is an efficient, cost-eff… https://t.co/vFhC7ITfZV
Bioclinica (2 weeks ago)
Reduce the number of user requirement iterations and UAT findings during the #IRT build process. With the agile app… https://t.co/TJt2sZlrFP
Bioclinica (2 weeks ago)
Don't compromise with manual systems and spreadsheets. As an entry-level system with phased implementation, Bioclin… https://t.co/qIpi1MESXw
Bioclinica (3 weeks ago)
According to our recent poll, 45% of respondents had neither a #CTMS nor an #eTMF system, while only 24% had both.… https://t.co/l4dKC7pBQo
Bioclinica (3 weeks ago)